Status:
ACTIVE_NOT_RECRUITING
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.
Detailed Description
The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy in order to det...
Eligibility Criteria
Inclusion
- Age of 18 years or older
- Scheduled for a colonoscopy or flexible sigmoidoscopy as part of the patient's standard care
- Can provide informed consent
Exclusion
- Subject is pregnant, a prisoner, or is under 18 years of age
- Patient is not able to undergo colonoscopy or flexible sigmoidoscopy
- Prior total proctocolectomy
- History of inflammatory bowel disease
- History of diabetes mellitus and are currently on medical diabetes therapy
- History of chronic kidney disease with an eGFR \< 60 mL/min/1.73m2
- Cancer diagnosis where the subject is receiving active therapy
- Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment
Key Trial Info
Start Date :
May 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05338307
Start Date
May 13 2022
End Date
June 30 2026
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104